Trial patients | Real-world patients | P-value | |
---|---|---|---|
n | 292 | 141 | |
Age at diagnosis in years; median (range) | 61 (37-84) | 64 (44-80) | 0.003 |
Age in categories; n (%) | 0.182 | ||
< 70 years | 241 (82.5) | 108 (76.6) | |
≥ 70 years | 51 (71.5) | 33 (23.4) | |
Gender; n (%) | 0.962 | ||
Male | 151 (51.7) | 74 (52.5) | |
Female | 141 (48.3) | 67 (47.5) | |
Stage; n (%) | 0.003 | ||
IIIB | 20 (6.8) | 0 | |
IV | 272 (93.2) | 141 (100) | |
ECOG PS; n (%) | < 0.001 | ||
0 | 84 (28.8) | 44 (31.2) | |
1 | 208 (71.2) | 90 (63.8) | |
2 | 0 | 7 (5.0) | |
Presence of brain metastases; n (%) | 0.114 | ||
Yes | 34 (11.6) | 25 (17.7) | |
No | 258 (88.4) | 116 (82.3) | |
Histology tumor; n (%) | 0.006 | ||
Adenocarcinoma | 270 (92.5) | 130 (92.2) | |
Large cell carcinoma | 7 (2.4) | 8 (5.7) | |
Adenosquamous | 3 (1.0) | 0 | |
Other | 11 (3.8) | 0 | |
Not otherwise specified (NOS) | 0 | 3 (2.1) | |
PD-L1 expression; n (%) | < 0.001 | ||
< 1% | 108 (37.0) | 33 (23.4) | |
1-49% | 57 (19.5) | 29 (20.6) | |
> 50% | 66 (22.6) | 10 (7.1) | |
Unknown | 61 (20.9) | 69 (48.9) | |
Subsequent systemic therapy; n (%) | 0.006 | ||
Yes | 124 (42.5) | 40 (28.4) | |
No | 168 (57.5) | 101 (71.6) |